I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

CTAD 2025

We will be contributing to topics related to
-
11:00 PM
Duration 60mins San Diego, USA
REACHED – a pilot study exploring electronic health records and digital assessments to identify potential participants from understudied populations for clinical studies in Alzheimer’s disease
Alexandria Wise-Brown, Erin Beck, Frank Boess, Frank Perilli, Giuseppe Filosa, Ira Goodman, Janice Smith, Kelly Coultes, Nicola Antonio Maiorano, Ruth Croney
01:35 AM
Duration 8mins San Diego, California, USA
Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer’s disease
Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Denise Sickert, Jakub Wojtowicz, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda
Duration 8mins San Diego, California, USA
TRONTIER 1 and 2: rationale and design of two identical Phase III trials to assess the efficacy and safety of trontinemab in early symptomatic Alzheimer’s disease
Catherine Mummery, Janice Smith, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopoulou, Christopher Lane, Paul Delmar, Gregory Klein, Carsten Hofmann, Luka Kulic
Duration 8mins San Diego, California, USA
The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer’s disease
Christopher Lane, Angeliki Thanasopoulou, Teresa Gleissl, Ross Paterson, Christina Rabe, Derrek Hibar, Alina Bauer, Imke Kirste, Annunziata Di Domenico, Tobias Bittner, Ruth Croney, Janice Smith
12:20 AM
Duration 15mins San Diego, California, USA
Pharmacokinetic / Pharmacodynamic Relationship of the Gamma-Secretase Modulator Nivegacetor in Presymptomatic Carriers of the PSEN1 E280A Mutation
Agnès Poirier, Enrique Gaspar, Dominik Lott, Stella Yilmaz, Tianxu Yang, Agnès Portron, Kalbinder Mahil, Tayo Bodede, David Aguillón, David Gordon, Robert Alexander, Thomas Mueggler, Stefan Sturm, Rosanna Tortelli, Irene Gerlach
03:15 PM
Duration 60mins San Diego, USA
Comprehensive Biomarker Assessment of the Gamma-Secretase Modulator Nivegacetor in Presymptomatic Carriers of the PSEN1 E280A Mutation
Agnès Poirier, Enrique Gaspar, Gwendlyn Kollmorgen, Dominik Lott, Stella Yilmaz, Tianxu Yang, Agnès Portron, Kalbinder Mahi, Tayo Bodede, David Aguillón, David Gordon, Robert Alexander, Thomas Mueggler, Rosanna Tortelli, Irene Gerlach
06:10 PM
Duration 15mins San Diego, California, USA
Brain volume changes with gantenerumab: relationship with amyloid removal
Christopher Belder, Frederik Barkhof, Gregory Klein, Janice Smith, Matteo Tonietto, Nick Fox
03:15 PM
Duration 60mins San Diego, USA
Automated linguistic and acoustic metrics of a smartphone-captured cued narration and recall assessment for detecting early memory and biomarker changes in early symptomatic AD
Raphael M. Ullmann, Arnaud M. Wolfer, Kami Kosek, Monika Zbytniewska-Mégret, Thanneer M. Perumal, Irma T. Kurniawan & Kirsten I. Taylor
Coming soon